Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections; and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. The Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido completed. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

Citius Pharmaceuticals Inc.

Citius Pharmaceuticals ( ($CTXR) ) has shared an announcement. On June 1, 2026, Citius Oncology reported Phase 1 data from an investigator-initiate...

Citius Highlights LYMPHIR Combo Data in Gynecologic Cancers

Analysts are intrested in these 5 stocks: ( ($CTXR) ), ( ($AMT) ), ( ($JAZZ) ), ( ($CTMX) ) and ( ($FATE) ). Here is a breakdown of their recent


Current Yield	N/A	Payout Ratio	N/A
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Record Date	N/A	Declaration	N/A
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CTXR	$0.57	-3.87%	230.75K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CTXR	$0.57	-3.9%	230.75K
3
4
5
6

CTXR

CTXR

Dividend Overview

Get Citius Pharmaceuticals Inc. Data in Excel

Get Citius Pharmaceuticals Inc. Data in Excel